Insiders · JAZZ

Peter Gray

Director at Jazz Pharmaceuticals plc (JAZZ)

Peter Gray has filed 3 insider reports with the SEC since August 2021, as director at Jazz Pharmaceuticals plc (JAZZ). Peter Gray made no open-market purchases or sales in the last 12 months. In the latest filing, on August 15, 2023, Peter Gray sold 1,241 shares of Jazz Pharmaceuticals plc (JAZZ) for $171K at an average of $138.16.

Filings
3
Companies
1
Bought on market
None
Sold on market
$1.64M

Companies where Peter Gray is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Jazz Pharmaceuticals plc logo
JAZZ
Jazz Pharmaceuticals plc
Director16,068$1.64M$239.77Aug 15, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Peter Gray with

Other insiders at the same companies

Questions about Peter Gray

What is Peter Gray's role at Jazz Pharmaceuticals plc?
Peter Gray reports to the SEC as director at Jazz Pharmaceuticals plc (JAZZ), according to the latest filing on August 15, 2023.
How many shares does Peter Gray own?
After the latest filing that states it, Peter Gray directly owned 16,068 shares of Jazz Pharmaceuticals plc (JAZZ). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Peter Gray bought or sold stock recently?
The most recent open-market sale was on August 14, 2023: sold 1,241 shares of Jazz Pharmaceuticals plc (JAZZ) for $171K at an average of $138.16.
How do I get alerts when Peter Gray files?
Follow Peter Gray on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Peter Gray (SEC CIK 0001576096). Totals count each trade once, skipping amendments whose original is on file, from Aug 10, 2021 on. View on SEC EDGAR